Shares of Novartis AG (NYSE:NVS) have earned a consensus rating of “Hold” from the twelve research firms that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $100.50.
Several brokerages have recently commented on NVS. UBS Group restated a “buy” rating on shares of Novartis in a research note on Friday, October 8th. JPMorgan Chase & Co. restated an “underweight” rating on shares of Novartis in a research note on Wednesday, July 28th. Zacks Investment Research downgraded Novartis from a “hold” rating to a “sell” rating and set a $96.00 target price for the company. in a research note on Monday, July 26th. Deutsche Bank Aktiengesellschaft downgraded Novartis from a “hold” rating to a “sell” rating in a research note on Monday, September 20th. Finally, Berenberg Bank restated a “buy” rating on shares of Novartis in a research note on Tuesday.
Shares of NVS stock traded up $0.18 during mid-day trading on Friday, hitting $82.61. The company’s stock had a trading volume of 52,871 shares, compared to its average volume of 1,916,302. The company’s fifty day simple moving average is $87.73 and its 200-day simple moving average is $88.99. Novartis has a 52 week low of $77.04 and a 52 week high of $98.52. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.56 and a current ratio of 0.80. The company has a market cap of $184.78 billion, a PE ratio of 20.91, a P/E/G ratio of 2.07 and a beta of 0.54.
Large investors have recently bought and sold shares of the stock. Evermay Wealth Management LLC bought a new stake in shares of Novartis in the 2nd quarter worth approximately $30,000. Allworth Financial LP raised its holdings in shares of Novartis by 76.0% in the 2nd quarter. Allworth Financial LP now owns 403 shares of the company’s stock worth $37,000 after purchasing an additional 174 shares during the period. RMR Wealth Builders raised its holdings in shares of Novartis by 222.7% in the 1st quarter. RMR Wealth Builders now owns 455 shares of the company’s stock worth $39,000 after purchasing an additional 314 shares during the period. Anfield Capital Management LLC bought a new stake in shares of Novartis in the 2nd quarter worth approximately $42,000. Finally, Parisi Gray Wealth Management bought a new stake in shares of Novartis in the 2nd quarter worth approximately $44,000. 9.90% of the stock is currently owned by institutional investors.
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals.
Featured Article: Operating Income
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.